



CURRICULUM VITAE

MARCH, 2017

PERSONAL INFORMATION

Name and current affiliation: **Bartolome Burguera, M.D. Ph.D.**
Professor of Medicine. Cleveland Clinic Lerner College of Medicine
Director of Obesity Programs. Staff Endocrinologist
Executive Medical Director. National Diabetes and Obesity Research Institute
Endocrinology & Bariatric Institutes
Cleveland Clinic

Date of Birth: May 27, 1962
Place of Birth: Santiago, Spain
Citizenship: USA/Spain

Education

School: School of Medicine, Santiago, Spain
Degree: MD
Dates: 1986

School: University of Santiago, Spain
Degree: MS
Master Thesis Title: Study of Growth Hormone secretion under different clinical conditions
Dates: 1987

School: University of Santiago, Spain
Degree: Ph.D.
Ph.D. Thesis Title: Regulation by glucocorticoids and estrogens of growth hormone
Dates: 1989
Ph.D. Thesis Committee: Prof. Felipe Casanueva, Prof. Carlos Dieguez, Prof. Rafael Tojo.

PROFESSIONAL APPOINTMENTS

Position/Rank: Executive Medical Director NDORI
Institution/Department: National Diabetes and Obesity Research Institute
Dates: 11/16 - present

Position/Rank: Staff/Director of Obesity Program
Professor of Medicine
Institution/Department: Department of Endocrinology, Diabetes, & Metabolism/Cleveland Clinic
Dates: 09/13 - present

Position/Rank: Staff Physician Son Espases/Endocrinology Physician/Director Research Unit
Vice-Director Instituto Universitario de Ciencias de la Salud
Institution/Department: Universidad Islas Baleares-Hospital Universitario Son Espases
Dates: 11/04 – 08/13

Position/Rank: Clinical Director
Institution/Department: Obesity Clinic UPMC
Dates: 04/01 - 11/04

Position/Rank: Assistant Professor of Medicine/Staff Physician, Endocrine Section
Institution/Department: Pittsburgh University Medical Center
Dates: 07/00 - 04/01

Position/Rank: Assistant Professor of Medicine/Staff Physician, Endocrine Section
Clinical Director Obesity Research Center
Institution/Department: Boston University School of Medicine
Dates: 07/99 - 6/00

ACADEMIC APPOINTMENTS

Current Position/Rank: Professor of Medicine
Institution/Department: Cleveland Clinic Lerner College of Medicine
Dates: 5/2015

Position/Rank: Assistant Professor of Medicine
Institution/Department: Mayo Medical School
Dates: 4/97 – 6/99

Position/Rank: Endocrinology Clinical fellowship
Institution/Department: Department of Medicine/Mayo Clinic
Dates: 7/96-6/99

Position/Rank: Part-time Attending Physician.
Institution/Department: Quello Clinic LTD.
Dates: 10/96-10/97

Position/Rank: Internal Medicine Residency
Institution/Department: Norwalk Hospital. Yale University School of Medicine.
Dates: 6/94-7/96

Position/Rank: Research Fellow
Institution/Department: Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN
Dates: 10/93-6/94

Position/Rank: Research Associate
Institution/Department: Section of Endocrinology, Department of Medicine, East Carolina University

School of Medicine, Greenville, NC
Dates: 2/89-8/93

Position/Rank: Visiting Research Fellow
Institution/Department: Molecular and Cellular Section Diabetes Branch, NIDDK, National Institutes of Health, Bethesda, MD
Dates: 8/89-2/90

Position/Rank: Research Fellow Neuroscience
Institution/Department: Laboratory, Department of Physiology, University of Santiago, Spain
Dates: 9/86-2/89

CERTIFICATION AND LICENSURE

Name of Board: National Board of Medical Examiners
Date of Certificate: 12/95

Name of Board: American Board of Internal Medicine
Date of Certificate: 8/98

Name of Board: American Board of Endocrinology (Board Qualified)
Date of Certificate: 8/99

Licensure State/Number: Minnesota Medical Licensure # 38981
Date Issued: (9/96)

Licensure State/Number: Massachusetts Medical Licensure # 160750
Date Issued: (9/99)

Licensure State/Number: Pennsylvania Medical Licensure #md-071798-L
Date Issued: (0/01)

Licensure State/Number: Ohio Medical License # 35. 121574
Date Issued: (07/13)

FELLOWSHIPS

Position/Rank: Research Fellow
Institution/Department: Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN
Dates: 10/93-6/94

Position/Rank: Endocrinology Clinical fellowship
Institution/Department: Department of Medicine/Mayo Clinic
Dates: 7/96-6/99

HONORS AND AWARDS

Title American Field Service (AFS), Diploma
Institution Wellesley Senior High School, Boston, MA
Year(s) 1979-1980

Title Xunta de Galicia, Doctoral Program
Institution Santiago University. Spain
Year(s) 1986-1987

Title CAYCIT. "Care of Laboratory Animals"
Institution Course at the Autonoma Barcelona University, Spain
Year(s) 1987

Title Fondo de Investigaciones, Doctoral Thesis

Institution Sanitarias de la Seguridad Social.
Year(s) 1988-1989

Title Xunta de Galicia. Postdoctoral
Institution East Carolina University School of Medicine, Greenville, NC
Year(s) 1990

Title Juvenile Diabetes Foundation International Fellowship (JDF)
Institution Juvenile Diabetes Foundation. Mentor: Dr. Jose F. Caro
Year(s) 1991-1993

American College of Physicians Connecticut Chapter . Finalist. 1995

Royal Academy Balearic Islands. Best clinical article. 2012

Academia Catalano/Balear Medicine. Best research Project. 2013

Galician of the Year (October 2015)
Gallego del año. Correo Gallego. Galicia Spain. Nov 2015.

MEMBERSHIP IN PROFESSIONAL SOCIETIES

(list Society, role and date received/ended) (i.e. Member, President, etc.)

Sociedad Gallega de Endocrinologia, Member	1987-present
Sociedad Española de Endocrinologia, Member	1987-present
Sociedad Española de Diabetes, Member	1988
American Diabetes Association, Member	1989-present
Endocrine Fellows Foundation, Member	1991
North American Association for the Study of Obesity, Member	1999-present
Asociacion de Medicos Gallegos (ASOMEGA)	2000-present
Sociedad Española de Obesidad,	2004-present
American Association of Clinical Endocrinologist, Member	2017

PROFESSIONAL SERVICES

Advisory Groups (i.e. foundation services, etc.)

Former Chair of Diabetes Working Group Longitudinal Assesment of Bariatric Surgery. 2003-06.
Institutional Review Board. Universidad de Pittsburgh. 2003-2004

COMMITTEE SERVICE

Vice-director Health Research Institute. Balearic Islands. Spain 2006
Fight Against Obesity National Commision. ENAOS (Ministerio de Sanidad). Spain 2005
Obesity prevention and treatment group. Conselleria de Salut. Illes Balears. Spain 2006
Research Committee. Son Espases University Hospital. Spain 2007
Member Spanish Commission Obesity Prevention. ENAOS. 2008
Experts Panel DIABESITY. Novo Nordisk. 2008
Professor Master in Medicine (Endocrinology). Balearic Islands University. 2010
Principal Investigator. Clinical trial Crescendo. Sanofi Labs. Son Espases University Hospital. Spain 2010
Principal Investigator. Clinical trial Scale. Liraglutide. Novo Nordisk. Son Espases University Hospital. Spain 2011
Principal Investigator. Clinical trial Diaprokal. Pronokal Labs. Son Espases University Hospital. Spain 2011
Nestle. Advisory Board. Optifast International Panel. 2013
Novo Nordisk Lifecycle Management Advisory Board.
CCF New Staff Advisory Council. Member.
CCF. SALUD. Hispanic-Latino Employee Resource Group. CCF. Member
CCF. Co-Director. 9th Annual Obesity Summit. October 2 – 3, 2014Cleveland, OH
CCF. Search Committee. CARDIOTHORACIC ANESTHESIOLOGY DEPARTMENT CHAIR.

Organization:

Member Board Spanish Society of Obesity 2010
Member Study Section Obesity. Spanish Society of Endocrinology 2011
Member Ethics Committee Islas Baleares 2012.
CCF. SALUD Hispanic/Latino Employee Resource Group.

REVIEWER

Journal of Clinical Endocrinology & Metabolism
Obesity and Metabolism
Endocrinology
Journal of Clinical Investigation
International Journal of Obesity
Diabetes Care
Clinical Endocrinology

TEACHING ACTIVITIES

Curriculum/Course Development

(Title, group, date, and time dedicated to activity)

1. **Director. International Symposium on Morbid Obesity: “Morbid Obesity an Interdisciplinary Approach,”** Palma, October 2006
2. INFORMED. Course Director. Jornadas de Actualización, Terapéutica en Obesidad, Palma, October 2006
3. Co-Director – **Curso Síndrome metabólico, Obesidad y riesgo cardiovascular,** Nuevos tratamientos, Palma de Mallorca, May 2007
4. Co-Director “**11th Mayo Clinic Endocrine Course,**” Palma de Mallorca, April 2008
5. Co-Director **Jornadas de Investigación, Illes Balears,** June 2008
6. Co-Director “**15th Mayo Clinic Endocrine Course,**” Palma de Mallorca, April 2012
7. Lecture on Bariatric Surgery to Graduate Students MMED52. Course Molecular mechanism in Human Disease. **Cleveland Clinic. Lerner College of Medicine.** Nov. 2013
8. 9th Annual Obesity Summit. Co-Director. October 2 – 3, 2014. Cleveland, OH
9. Tutorial, Prevalent skin lesions in obese patients, live on the Obesity Hyperguide. 2015
10. 10th Annual Obesity Summit. CCF. Co-Director. October 2 – 3, 2015 Cleveland, OH
11. 11th Annual Obesity Summit. CCF. Co-Director. September 29-30, 2016 Cleveland, OH
12. 1st Diabetes and Obesity Summit. Hawaii. Co-Director. January 2017.
13. 12th Annual Obesity Summit. CCF. Co-Director. September 28-29, 2017 Cleveland, OH

Presentations

1. **International Symposium on Hormonal Regulation of Growth**
Austria, 1988
2. **Sociedad Española de Endocrinología,** Congreso Nacional Santiago, Spain, 1991

3. **Post-Graduate Course on Molecular Mechanisms of the Endocrine System**,
Foundation Ramon Areces, La Toja, Spain, 1991
4. **ECU Diabetes Series**, Greenville, NC, 1992
5. **Sociedad Española de Endocrinología**, Congreso Nacional. Toledo, 1994
6. **The Connecticut Chapter of the American College of Physicians**, 1995
7. **2nd Reunión Medicos Gallegos**, Orense, España, 1997
8. **Orange County Endocrine Society**, California, 1999
9. **Boston University. Obesity Center**, 1999
10. **Curso de Post-Grado en Molecular Mecanismos del Sistema Endocrino**,
Fundación Ramón Areces. Orense, 1999
11. **The Society for the Study of Ingestive Behavior, Meeting annual**. Dublin, 2000
12. Endocrine Grand Rounds. **Boston University**. Boston, 2000
13. Obesity and Diabetes, Diabetes in Office Practice, Dedham. **Boston University**. Boston, 2000
14. **Diabetes 2001. State of the Art in Diabetes, Obesity and Nutrition**,
Sociedad Española de Diabetes, Madrid, 2001
15. The Obesity Epidemic, 'Practical Treatment of Obesity: Medical and Surgical Options,' **UPMC**
Pittsburgh, 2001
16. Pathophysiology of obesity: Diabetes State of the Art in Diabetes, Obesity and Nutrition,
Sociedad Española de Obesidad. Madrid, 2001
17. "Obesity therapy," Division of Endocrinology Grand Rounds, **Boston University**, 2001
18. Tratamiento de la Obesidad, **Hospital Clinico**, Madrid, 2001
19. "Therapeutical approach to morbid obesity," Medicine Grand Rounds, **UPMC**. Pittsburgh,
2002
20. "Ethiopathogenesis and therapy of obesity," Women Health Program. **UPMC**. Pittsburgh,
2002
21. "Impact of weight loss on obesity comorbidities," Practical treatment of obesity medical and
surgical options, **UPMC Obesity Course**, 2002
22. "Obesity, Obesity, is it diet or genes?," Internal Medicine Review Course, **UPMC Obesity Course**
2002
23. Update on Medical Management of Obesity, **Morbid Obesity Symposium**, Lake Tahoe, California
Feb 2003
24. Simposio "Diabetes, de la enfermedad ateroesclerótica a la enfermedad cardiovascular,"
Hospital Clinico, Barcelona, May 2003

25. **Sociedad Española de Endocrinología**, Congreso Nacional Badajoz, Spain, May 2003
26. IFATS Symposium, Neuroregulation of appetite, Mallorca. Spain, May 2003
27. Obesity Therapy, 4th Annual MIS Symposium, Whistler, British Columbia, February 2004
28. **Curso de Post-Grado en Molecular Mecanismos del Sistema Endocrino**, Fundación Ramón Areces, Santiago de Compostela, Noviembre 2004
29. **II SALON INTERNACIONAL DE LA SALUD**, Morbid Obesity : an endocrinological perspective, Santiago, March 2005
30. **Congreso Nutrición Salud Sociedad**, Impact of weight loss on type 2 diabetes Mellitus Bilbao, June 2005
31. **Sumer Course El Escorial**, Impacto de la Cirugía Bariátrica sobre la Diabetes Tipo 2, Madrid, July 2005
32. Neuroregulación de Apetito, Reunión sobre Obesidad Mórbida de la **Fundación de Investigación Científica de la Mutua Madrileña**, Madrid, October 2005
33. **Conferencia de Clausura de la Sociedad Española de Obesidad**, Epidemia de Obesidad. Lecciones Americanas para una Realidad Española, Murcia, October 2005
34. Morbid Obesity: an endocrinological Perspective, **Hospital Universitario de Las Palmas**, November 2005
35. **European Health Forum**, Obesity, a public health problem, Santiago, December 2005
36. **Residents Course. Sociedad Española de Endocrinología**, February 2006
37. Obesity and cardiovascular risk. **Congreso Sociedad Catalana de Diabetes**, March 2006
38. New obesity therapies, **Congreso de Obesidad, Universidad de Navarra**, March 2006
39. Ghrelin and bariatric surgery, **Hospital Clinic**, Barcelona, April 2006
40. **Director Internacional Symposium on Morbid Obesity:** “Morbid Obesity an Interdisciplinary Approach,” **Palma**, October 2006
41. Academia Medica de Baleares, Reunión de Obesidad, Palma, October 2006
42. **International Conference on New Trends in the Management of Morbid Obesity**, Cambios Hormonales después de la Cirugía, Barcelona, November 2006
43. IV Reunion Internacional “ **La alimentación y la Nutricion del Siglo XXI**, Lecciones americanas para la realidad Española, Baiona, November 2006
44. **VI Congreso Sociedad Canaria de Endocrinología y Nutrición**, La Palma, April 2007
45. Endocrine Issues after Bariatric Surgery, **European Congress of Endocrinology**, Budapest, May 2007

46. Nutrición en Cirugía Bariátrica, “ **Curso de Nutrición Enteral para farmacéuticos Hospitalarios,**” Palma, November 2007
47. **11th Mayo Endocrine Course,** Evaluation of the morbidly obese patient, Palma de Mallorca, April 2008
48. **Jornadas de Investigación Illes Balears,** Investigación en Hospital Son Dureta, Palma de Mallorca, June 2008
49. Chairman Mesa Obesidad Morbida, **Congreso DIABESITY,** Santiago de Compostela, October 2008
50. Chairman Mesa diabetes y Obesidad Morbida, **Symposium Obesidad Mórbida Mutua Madrileña Madrid,** November 2008
51. **Reunion Sociedad Balear de Hipertensión,** Obesidad e hipertensión, Palma de Mallorca, November 2008
52. **1^{er} Curso Avanzado Obesidad,** Nuevos tratamientos Obesidad, Sociedad Española de Obesidad, Madrid, February 2009
53. **Moderador y speaker, Symposium Diabesity,** Sociedad Española de Diabetes, Tenerife, March 2009
54. **Congreso Sociedad Española de Endocrinología,** Obesity associated to antipsychotic therapy, Zaragoza, June 2010
55. **Reunión Anual CIBER Obesidad,** “TRAMOMTANA and ACTYBOSS,” September 2010
56. **Congreso Sociedad Española de Obesidad,** Moderador Mesa sobre Diabesidad. La Coruña, October 2010
57. **III Congreso Nacional de Laboratorio Clínico,** Regulación de apetito, Obesidad y apnea del sueño Valencia, October 2010
58. **4^o Curso de Avances en el tratamiento de la Obesidad,** Fundación Médica Mutua Madrileña, Tratamiento Médico Obesidad Mórbida, Madrid, October 2010
59. **Congreso Sociedad Balear de Cardiología,** Impacto de la pérdida de peso sobre el RCV, Palma, October 2010
60. **Diabesity Novo Nordisk Symposium,** Incretins and bariatric surgery, Iguazú. Argentina, March 2011
61. Chairman **Symposium on hyperprotein Diets,** Spanish Endocrine Society Meeting, Santiago, May 2011
62. **Spanish Endocrine Society Course,** Diabetes and bariatric surgery, Madrid, October 2011
63. **Spanish Obesity Society Meeting,** Chairman Behavioral therapy and obesity, October 2011
64. **Diabesity International Symposium,** Debate: VLCD, Sevilla, November 2011
65. **Galician Medical Association,** Diabetes and bariatric surgery, Salvador de Bahia, Brasil, April 2012
66. **Spanish Obesity Society Review Course,** Closing Lecture, TRAMOMTANA: Behavioral therapy and obesity, El Escorial, Madrid, September 2012
67. **Madrid Real Academia de Medicina,** Life style interventions in Obesity Therapy, October 2012
68. Medical Therapy of Morbid Obesity. Grand Rounds. **Mayo Clinic.** August. 2012
69. Medical Approach to Morbid Obesity. Grand Rounds. **Cleveland Clinic.** January. 2013

70. Life Style Interventions as treatment of Morbid Obesity. **Cleveland Clinic Obesity Summit**. Oct 13
71. TRAMOMTANA: Interdisciplinary therapeutic approach to Morbid obesity. **VII Latino Metabolic Meeting**. San Antonio. TX November.2013
72. Lecture on Bariatric Surgery to Graduate Students MMED52. Course Molecular mechanism in Human Disease. **Cleveland Clinic. Lerner College of Medicine**. Nov. 2013
73. Obesity therapy. Universidad Nebrija. Ciencias de la Salud. Madrid April. 2014
74. **Novo Nordisk Lifecycle Management Advisory Board**. New York City. August 14th -16th. 2014
75. What to do with morbidly obese patients who do not respond to bariatric surgery? Obesity Symposium. Mutua Madrilenia Medical Fundation. **Madrid. October 2014**
76. Aspectos clínico-prácticos: Nuevos enfoques en el abordaje médico del tratamiento de la obesidad mórbida. 8th. Curso Internacional sobre Obesidad. **MIAMI, FLORIDA November. 2014**
77. Medical Therapy Morbid Obesity. Congreso Panamericano de Medicina Interna. Los Cabos, Mexico. November 2014.
78. Hispanic Health Committee of the Cleveland Hispanic Roundtable. Keynote speaker. Obesity Prevention and Treatment. Cleveland. April 2015.
79. Congreso Nutricion UNIVA Guadalajara. Mexico Nov. 2105
80. Sociedad Espanola de Cirugia de la Obesidad. Barcelona 2016.
81. Sociedad Espanola de Endocrinologia. National Meeting. Malaga. Oct 2016
82. Sociedad Espanola de Obesidad. National Meeting. Sevilla. March 2017

Visiting Professorships

(title, group, date; including Grand Rounds)

1. Medical Therapy of Morbid Obesity. Grand Rounds. **Mayo Clinic**. August. 2012
2. Medical Approach to Morbid Obesity. Grand Rounds. **Cleveland Clinic**. January. 2013
3. Obesity therapy. Universidad Nebrija. Ciencias de la Salud. Madrid April. 2014

Trainees / Mentees (list former graduate/post-graduate students, years of training and their current status. As applicable, list as: medical students, master's level trainees, Ph.D. candidates and fellows [post-doctoral and clinical])

(name, years of training, current status)

Graduate students (Universidad de Santiago)

1. Covadonga Muruais, 1987-1990. Dentist. Private Practice.
2. Clara Álvarez, 1987-1990. Professor of Physiology. Santiago University. Spain
3. Roseta Teijeiro, 2003. Pharmacist. Spain
4. Ana Canton. Endocrinologist. El Ferrol Spain.

Supervision of Investigation:

1. **East Carolina University**
James Busby. Master Thesis, 1991-1993. Biochemist. North Carolina.
Nivaldo Parcianello, 1992 Chemist. Brasil
2. **Mayo Clinic**
Jesse Lamsam, 1997-99. Technician

Karen Laakso, 1998-99. Technician

3. **Boston University**

Guangde Li, 1999-00. Technician

4. **University of Pittsburgh**

Ami Brunetto, BS, 2000. Technician

Dr. Fadi Samaan, 2001. Medical Student

Dr. SuZanne Chaves, 2001. Clinical Fellow

Summer Student Minority Program: Charity Kates, 2003.

Visiting Physicians: Dr. Alfonso Leal (Spain), 2000
Dr. Isabel Jimenez (Spain), 2001

5. **Hospital Son Espases, 2007-2013**

PhD and Master students: Josefina Olivares, Baltasar Cortes, Antonio Escudero, Alberto Pagan, Juan Tur, Antonio Palomero

6. **Cleveland Clinic Foundation**

a.- **Research fellow:** Amani Hag MD. June 2014.-June 2015

b.- **Cleveland Clinic International Physician Observership Program:**

Daniel Roca. CWRU. June 2014.

Guillermo Bonet. University of Navarra Spain. June 2014

Noelia Gros Herguido. Hospital Virgen del Rocío. Spain. March and April 2015.

Maria Arnoriaga. Hospital Clinico. Madrid. Spain May-June 2016.

Suset Duenas. Hospital Virgen del Rocío. Spain. March 2017

Teaching Material Produced

(title, date developed)

1. Endocrine Disorders Course. PBL. Obesity lectures. UPMC. 2003. 2004
2. Lectures Obesity Module. Master in Health Sciences. Balearic Island University. 2012
3. Contributor to "Clinical Scholar in Metabolic/Diabetes Surgery" Fellowship Program. Dr. Ali Aminian.
4. Obesity Module. Case Western Reserve School of Medicine. 2016

Teaching Administration (e.g. residency directorship)

(title, facility, date)

5. Director Obesity Module. Master in Health Sciences. Balearic Island University. 2012
6. Set up of Medical Obesity Clinic. Joint effort BMI and EMI. Endocrine and bariatric surgery fellows rotating.

Teaching Activities (e.g. lectures to trainees, teaching rotations)

(Activity, time spent, date)

1. During the 6 years (1998-2004) that I was Assistant Professor in Mayo Medical School, Boston University and University of Pittsburgh Medical Center, I actively participated in the Endocrinology teaching Medical School curriculum during a period of 3-4 weeks every year. In addition to medical students, I also gave lectures to residents and fellows as part of the Endocrinology fellowship and Internal medicine curriculum in these three US Institutions, as well as Son Espases University Hospital in Spain (2004-2013).
2. Set up of medical Obesity Clinic. Joint effort BMI and EMI. Endocrine and bariatric surgery fellows rotating.
3. Lectures to Endocrine fellows. Rotating supervisor of fellows endocrine Clinic. Inpatient Diabetes and Endocrine Service with Internal Medicine residents and Endocrine fellows.
4. Cleveland Clinic International Physician Observership Program: teaching activities to Spanish and Turkish physicians.
5. Facilitator. Obesity Module. Second Year. Case Western Reserve School of Medicine. 2016
6. Cleveland Clinic Lerner College of Medicine. Obesity Lectures.

RESEARCH SUPPORT (list recent to oldest)

(granting agency, title of project, principal investigator, percent of effort, total direct costs awarded, dates inclusive [start – end])

Collaboration in clinical trials and Research projects at CCF:

Ongoing projects:

1. - Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently (**STAMPEDE**) trial. PI: Philip Schauer MD.
2. - Effect of a **Cross Fit** Lifestyle Intervention on Insulin sensitivity, cardio metabolic risk factors and Quality of life in obese type 2 diabetic individuals. PI: Dr. John Kirwan.
- 3.- A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the **EndoBarrier** Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Metformin and/or Sulfonylurea Anti-Diabetes Agents.
PI: Dr. Kennedy and Dr. Brethauer

Submitted/under review:

1. - Weight loss approach for post-bariatric surgery patients. Specific Aim 1: Determine the effects of Lorcaserin+standard of care vs. placebo+standard of care on obesity management in post-bariatric subjects related to weight loss/regain. PI: Dr. Sangeeta R. Kashyap.
2. - Suboptimal weight loss after bariatric surgery at CCF. A snapshot of the current problem. PI: Philip R Schauer
3. - Efficacy of a behavioral intervention for reversing weight regain following RYGB surgery. PI: Dr. Leslie Heinberg. (BB 5% salary support).
4. - Presurgical Impact of Lorcaserin therapy in morbidly obese patients. Aim 1: Determine the effect of lorcaserin plus standard medical care (Lorcaserin+) vs. control (standard medical care alone) on operating time and surgical complications. PI: Dr. John Kirwan. (BB 5% salary support)
- 5.- Insulin sensitivity in muscle/pancreas axis. NIH R21 grant. PI: Dr. John Kirwan. (BB 5 % salary support).

Development of new projects as PI at CCF:

1. - Proposed Employee Health Plan Weight Management Program (Mediterranean Diet, Supplement and PSMF) for High BMI Employees. This program has been reviewed with Dr. Rogan and is under consideration. This program is directed to employees with BMI >35 and who are non-surgical candidates.

2. - Interdisciplinary Obesity therapy Program. Objective: To develop an optimal non-surgical weight loss program to offer patients with BMI > 35 non-surgical candidates. It is our goal to accomplish a 10-15% weight after 6 months of intervention and weight loss maintenance after 30 months. This program will start in August. It provided three different diets (Mediterranean Diet, Supplement and PSMF) and it is provided in the context of Shared medical appointments). This program is offered in collaboration with BMI Behavioral team (Dr. Leslie Heinberg) and Cardiac Rehabilitation (Dr. Gordon Blackburn).

3- ACTIVHOS: Activity, Cognitive Therapy, Incentives, in Hispanic Overweight Students. Specific Aim 1: Determine the effects and impact that an incentive-driven, innovative after- school pilot intervention, which combines an exercise program with nutritional lectures vs. control group on body composition, physical fitness in adolescents. PI: B. Burguera. This program is under development with the support of the Office of Diversity (Ms. Diana Gueits) and it is our goal to provide to mainly Cleveland High Schools with a majority of Hispano students.

4. - KP program. /Questionnaire technology for the outpatient programs EMI. Endocrinology team: Drs. Zimmerman and Burguera, Jennifer Tonkli, Beth Abood and Ron Gambino. TKP/Questionnaire technology for our outpatient programs. Goal: to obtain patient medical information (on diabetes history and control, life style and review of systems) in the waiting room and have the information populated directly into EPIC, with the help of portable electronic tablets.

COMPETITIVE RESEARCH GRANTS

<p>Research Grant, R03 DK 41191-01 National Institutes of Health (Designated Visiting Researcher), Bethesda, MD</p>	1989
<p>Research training Grant, DK-07352 National Institutes of Health Department of Medicine, Mayo Clinic, Rochester, MN</p>	1996-1998
<p>Research Grant from Fundacion Salud 2000. Title: Regulation Of Growth Hormone by Free Fatty Acids. Co-Investigator (Dr. FF Casanueva, P.I.)</p>	1996-1988
<p>Principal Investigator. Research Grant from Eli Lilly Title: Obesity a reset of the cerebral adipostat? \$115,000/yr.</p>	1997-1999
<p>Principal Investigator. Research Grant from Eli Lilly Title: Osteogenic effect of leptin. (\$15,000)</p>	1998-1999
<p>Regulation of appetite University Pittsburgh (\$100,000 yr.) Department of Medicine</p>	2000-2003
<p>Principal Investigator (30,000 yr.) Copeland Fund. Pittsburgh Foundation Title: Hypothalamic gamma knife radiosurgery as therapy for obesity</p>	2001-2003
<p>Co-PI (200,000 yr.) RW. Johnson Pharmaceutical Institute Evaluation of antidiabetic effect of topiramide</p>	2001-2002
<p>Principal Investigator (15,000 yr.) Obesity and Nutrition Research Center University of Pittsburgh Title: Evaluation of brain serotonin receptors in obesity. A Positron Emission Tomography study.</p>	2001-2003
<p>CO-PI. 70,000. Pittsburgh Foundation. Malfunction of hypothalamic cross-talk as a cause of obesity.</p>	2001-2003
<p>Eli Lilly (50,000). The Global Hypopituitary Control and Complications Study. Pittsburgh Site. Principal Investigator.</p>	2003-2008
<p>Principal Investigator (200,000) Elekta Instruments Title: Hypothalamic gamma knife radiosurgery as therapy for obesity</p>	2003-2005

Co-Investigator NIH LOOK AHEAD. Pittsburgh site.	2000-2011
Coinvestigator. Chair Diabetes Working Group. NIH. RFA. Bariatric Surgery Clinical. Research Consortium. Impact of gastric bypass surgery on insulin sensitivity. (200.000 yr.).	2003-2005
Pfizer Pharmaceuticals. (PI). (E 6,000) Impacto del traumatismo craneoencefálico sobre la función hipofisaria.	2006
Novartis Laboratories. (E 3,000) Impacto de Optifast sobre el peso de pacientes con obesidad Morbida en lista de espera para cirugía bariátrica.	2006
Roche Laboratories. (E 6,000) Estudio Tramontana. Medical Therapy of Morbid Obesity: Medical therapy, behavioural therapy and physical activity.	2006
Abbott Laboratories. (E 24,000). (PI) Medical Therapy of Morbid obesity.	2006
Mutua Madrilená. (E55,000). Insulin sensitivity before and after bariatric surgery	2008-12
Proyecto FIS: PI071250. PI. Papel de las Incretinas en la Resolución de la Diabetes Mellitus tipo 2 después de Cirugía Bariátrica. € 72,000	2007-2011
Consejería de Economía, Hacienda e Innovación. Convocatoria de ayudas para la realización de proyectos I+D+i. Entidades Participantes: SD Assessors, S.A. y Unidad de Investigación del HOSPITAL SON DURETA. € 40,000	2007-2009
ISCIII. Convocatoria Ayudas Económicas para Infraestructura. IF07/36202. PI. € 70,000.	2008
CAIBER. (CAI08/01/0046). PI. Hospital Son Dureta en colaboración con Atención Primaria. € 210,000.	2008-2013
BIOBANCO. Co-PI.Convocatoria del SCIII en 10/08 This Biobank is associated to our research Unit CAIBER. € 170,000.	2008-2013
ISCIII. Coinvestigador. Convocatoria Ayudas Económicas para Infraestructura. IF07/36202. Densitometer. € 108,000.	2009
Conselleria de Salut. Direccion General Salud Pública. € 40,000. Proyecto ACTYBOSS. Prevención Obesidad en adolescentes	2009-12
CONSELLERIA DE SALUT. Papel de las Incretinas en la Resolución de la Diabetes Mellitus tipo 2 (T2DM) después de cirugía bariátrica. € 6000.	2009

ISCIII. Spanish National Institute of Health. 2009-12
Development of a Health Research Institute
3.168.137 €

ISCIII. Reseach Unit CAIBER. (CAI08/01/0046). 2009-12.
€ 210,000.
Research Unit
PI. Hospital Son Espases

Spanish National Institute of Health. 2012-14
Convocatoria para la concesión de ayudas
para el fomento de de la
investigación clínica independiente.
Metabolic surgery compared to Liraglutide.
IP. Clinical trial. ORIENTD. 133.000€

PI12/02974 Spanish National Institute of Health. 2012-15
Tratamiento Interdisciplinar Intensivo de la Obesidad Mórbida:
Tratamiento presencial Vs. virtual: Un Ensayo Clínico Aleatorizado
de 24 meses de duración con un seguimiento de seis meses.
IP. Clinical trial. E-TRAMOMTANA. 56.265€

E-TRAMOMTANA - Telematic interdisciplinary approach to obesity. The main objective of the E-TRAMOMTANA study is to evaluate, in patients with morbid obesity, the impact of an intensive interdisciplinary program of weight loss, which includes: Health education in areas of nutrition and physical activity, group therapy, support in the change process and interdisciplinary focus. We will compare the results using face-to-face interdisciplinary intensive therapy with those obtained through a virtual platform in patients with morbid obesity. This study is a randomized, control clinical trial of 24-months duration with an additional follow-up period of six months, aimed to evaluate the differences between Face-to-Face versus Virtual Treatment in two groups of participants receiving an Intensive Interdisciplinary Treatment of Morbid Obesity.

Source/Project # or type (P.I.): Ministry of Innovation. Balearic Islands. Competitive
Period (Annual Direct/Indirect): 2012-13. (€7,000)
PI12/02974 Spanish National Institute of Health. 2012-15 (56.265€).

.-Study ORIENTD. Obesity Research on Incretins: The aim of the study is to evaluate the role of metabolic Surgery in the improvement of type 2 diabetes in patients with grade I obesity compare to medical therapy, insulin and lyraglutide. This is a multicenter, open, controlled intervention with random assignment and three parallel branches of two-year and 3 years of follow-up. In collaboration with Drs. Xavier Gonzalez and Alberto Pagán (HUSE), the Clinical Hospital of Madrid (Dr. MA Rubio, Dr. Antonio Torres, society President European Bariatric Surgery and the Hospital Virgen del Rocío (Dr. PP García Luna and surgeon Salvador Morales).

Source/Project # or type (P.I.): ISCIII. Ministry of Health. Competitive
Period (Annual Direct/Indirect): 2012-14. (€132,000)
Role, % Effort: PI. No salary

.-Study TRAMOMTANA: (Interdisciplinary treatment of the morbid obesity: behavior therapy, Mediterranean diet and physical activity). The objective of this study is to evaluate the impact of a program of intensive interdisciplinary, non-surgical, weight loss program, (including: education for health in nutrition, physical activity, Mediterranean diet) compared to conventional medical therapy and surgery, in patients with morbid obesity. This study was conducted in collaboration with the Division of Endocrinology, general surgery, Pulmonary (sleep unit) and the financial Unit of our hospital. We have carried out more than 250 health education sessions.

Source/Project # or type (P.I.): Mutua Madrileña Medical Foundation. Competitive
Period (Annual Direct/Indirect): 2008-12. (\$50,000)
Role, % Effort: PI. No salary

.-ISI study: Role of the Incretins in the resolution of Diabetes Mellitus type 2 (T2DM) after bariatric surgery. The objective of this study is to advance our understanding of the regulation of glucose metabolism in obesity and evaluate the mechanism responsible for improving insulin sensitivity (SI) and metabolic syndrome after biliopancreatic diversion (BPD) in individuals with T2DM. Study funded by the Spanish National Institute of Health (ISCIII) (78,000 €). This study is in collaboration with the Division of Endocrinology, general surgery, and pulmonary (of our hospital) and Dr. Antonio Vidal Puig (Univ. of Cambridge).

Source/Project # or type (P.I.): ISCIII. Competitive
Period (Annual Direct/Indirect): 2007-11. (\$75,000)
Role, % Effort: PI. No salary

-ACTYBOSS: Activity, Behavioral Therapy in Young obese Overweight Subjects. Obesity prevention clinical trial, which consists in incentive-driven, after-school intervention program which involves free supervised exercise sessions and nutritional lectures, where children received credit points as a reward for the hours spent exercising and attendance to the lectures. The credits-earned points obtained are exchanged for gifts. These points are redeemed for gifts, vouchers for healthy meals, trips, tickets to sporting events and shows, etc. This study is in collaboration with the Department of Pediatrics of our Hospital and researchers of the IUNICS.

Source/Project # or type (P.I.): Balearic Island Ministry of Health. Competitive
Period (Annual Direct/Indirect): 2009-12. (€40,000)
Role, % Effort: PI. No salary

BIBLIOGRAPHY (*published or in press only; should be numbered and in chronological order; list ALL authors*)

Peer Reviewed Articles

(Author [list all authors, not: et al.], title of article, journal and year, volume, pages)

1. Casanueva FF, Borrás CG, Burguera B, Muruais C, Fernández M, Devesa J. Steroids and neuroendocrine function in anorexia nervosa. **J Steroid Biochem** 1987; 27:635-640.
2. Casanueva FF, Borrás CG, Burguera B, Lima L, Muruais C, Tresguerres JAF, Devesa J. Growth hormone and prolactin secretion after GHRH administration in anorexia nervosa patients, normal controls and normal controls pretreated with tamoxifen. **Clin Endocrinol** 1987; 27:517-523.
3. Casanueva FF, Burguera B, Tome M, Lima L, Tresguerres JAF, Devesa J, Dieguez C. Depending on the time of administration, dexamethasone potentiates or blocks growth hormone releasing hormone-induced growth hormone release in man. **Neuroendocrinology** 1989; 47:46-49.
4. Peñalva A, Burguera B, Casabiell X, Tresguerres JAF, Dieguez C, Casanueva FF. Activation of cholinergic neurotransmission by pyridostigmine, reverses the inhibitory effect of hyperglycaemia on growth hormone releasing hormone-induced GH secretion in man; suggesting that glucose acts through hypothalamic release of somatostatin. **Neuroendocrinology** 1989; 49:551-554.
5. Burguera B, Muruais C, Peñalva A, Casanueva FF, Dieguez C. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man. **Neuroendocrinology** 1990; 51:58-62.
6. Casanueva FF, Burguera B, Muruais C, Dieguez C. Acute administration of glucocorticoids: a new and peculiar stimulus of growth hormone secretion in man. **J Clin Endocrinol Metab** 1990; 70:234-237.
7. Burguera B, Werner H, Sclar M, Shen-Orr Z, Stannard B, Roberts Jr CT, Nissley SP, Vore SH, Caro JF, LeRoith D. Liver regeneration is associated with increased expression of the insulin-like growth factor II/mannose 6-phosphate receptor. **Mol Endocrinol** 1990; 4:1539-1545.
8. Burguera B, Couce M, Lage M, Vina MD, Dieguez C, Casanueva FF. Lack of effect of TRH secretion of growth hormone induced by dexamethasone. **Rev Clin Esp** 1990; 188:65-67.
9. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts Jr., CT, LeRoith D. Regulation of insulin-like growth factor receptors gene expression in diabetic kidney. **Diabetes** 1990;39: 1490-1497.
10. Benitez L, Mallo F, Alvarez C, Burguera B, Sanchez-Franco F, Dieguez C. Estrogen-dependent effects of bombesin on in vivo growth hormone secretion in the rat. **Neuroendocrinology** 1991;52:608-703.
11. Alvarez C, Mallo F, Burguera B, Cacicedo L, Dieguez C, Casanueva FF. Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses of GHRH in the rat. **Neuroendocrinology** 1991;53:185-189.
12. Burguera B, Long S, Frank HB, DiMarchi R, Caro JF. Binding of insulin-like growth factors, proinsulin and proinsulin analogs to human liver, muscle and adipose tissue receptors. **J Clin Endocrinol Metab** 1991; 72:1238-1241.

13. Burguera B, Madigan T, Mustafa SJ, Frank HB, DiMarchi R, Caro JF. The interaction of proinsulin with insulin-like growth factors I and II receptors in smooth muscle membranes from bovine coronary arteries. **Av Diabetol** 1992; 5:187-196.
14. Usala AI, Madigan T, Burguera B, Sinha MK, Caro JF, Powell JG, Butler PC. Insulin-like growth factor I treatment of ketoacidosis in an insulin-resistant adolescent with type I diabetes mellitus. **New Engl J Med** 1992; 327:853-857.
15. Casanueva FF, Burguera B, Alvarez CU, Zugaza JL, Pombo M, Dieguez C. Corticoids as a new stimulus of growth hormone secretion in man. **J Ped Endocrinol** 1992; 5:85-90.
16. LeRoith D, Werner H, Burguera B, Roberts Jr, CT, Mulrone S, Haramati A. The insulin-like growth factor family of peptides, binding proteins and receptors: their potential role in tissue regeneration. **Advances in Experimental Medicine and Biology**, 1992;21-30.
17. Mayo F, Alvarez CU, Benitez L, Burguera B, Coya R, Casanueva FF, Dieguez C. Regulation of GHRP-6 induced GH secretion in the rat. **Neuroendocrinology** 1993; 57:247-256.
18. Burguera B, Dudek R, Couce ME, Sliker ZT, Heath WF, Caro JF. Glut-2 expression in the liver is up-regulated by glucose administration. **Av Diabetol** 1993; 7:23-26.
19. Burguera B, Tapscott EB, Elton CW, Usala AL, Pories CW, Sakano K, Dohm GL. IGF-II stimulation of glucose uptake in human muscle is not mediated by IGF-II receptor (IGF-II/man 6-PR). **Biochem J** 1994;300:781-785.
20. Usala AL, Madigan T, Burguera B, Sinha MK, Powell JC, Usala SJ. Intravenous, but not subcutaneous, insulin-like growth factor I induces sustained insulin sensitivity in type I diabetes mellitus complicated by severe resistance. **J Clin Endocrinol Metab** 1994; 79:435-440.
21. Burguera B. IGF-I treatment in extreme insulin-resistance syndromes. **Ann Int Med.** 1994; 121:549-550.
22. Burguera B, Dudek RW, Caro JF. Liver GLUT-2 protein is not upregulated in non-insulin-dependent diabetes. **Hum Metab Res.** 1995;27:341-343.
23. Guo Z., Nielsen S., Burguera B, Jensen MD Free fatty acid turnover measured using ultralow doses of [U-13C] Palmitate. 1997. **J Lipid Res** 38:1888-95
24. Couce ME, Burguera B, Parisi JE, Jensen MD, Lloyd RV. Localization of the leptin receptor (OB-R) in the human brain. 1997. **Neuroendocrinology.** 66:145-50
25. Thomas T, Gori F, Jensen MD, Burguera B, Riggs BL. 1999. Leptin acts on human marrow stroma cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. **Endocrinology.**140:1630-1638
26. L. Jin, Burguera B, Couce ME, Lamsam J, K. Kovacs, Lloyd RV. 1999 Leptin receptor (OB-Rb) expression in normal and neoplastic human pituitaries. Regulation of pituitary cell proliferation by leptin.. **J Clin Endocrinol Metab** 84:2903-2911
27. Burguera B and Garib H. THYROID INCIDENTALOMAS. Diagnostic and therapeutic approach. 2000. **Endocrinology and Metabolism Clinics of North America.** 29:187-203.
28. Burguera B, Proctor D, Dietz N, Guo Z, Joyner M, Jensen M. Leg free fatty acid kinetics during exercise in men and women. 2000. **Am J Physiol Endocrinol Metab** 278:E113-E117
29. Burguera B, Couce ME, Long J, Lamsam J, Parisi JE, Lloyd RV. 2000 The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. **Neuroendocrinology.** 61:187-195
30. L. Jin, Burguera B, Couce ME, K. Kovacs, Lloyd RV. Leptin receptor (OB-Rb) expression in rat pituitaries. **Endocrinology** 2000 Jan; 141:333-339.

31. Thomas T, Burguera B, Melton LJ, Atkinson EJ, Riggs BL, Khosla S. Relationship of serum leptin levels with body composition, sex steroids and insulin levels in men and women. 2000. **Metabolism** . 49:1278-1284
32. Burguera B, Curran G, Couce ME, Lamsam J, Cleary M, Poduslo J. Obesity is associated with a decreased of leptin transport across the blood brain barrier and up regulation of leptin receptor in the hypothalamus. 2000. **Diabetes**. 49:1219-1223
33. Burguera B & Couce ME. 2000. Leptin access into the brain: a saturated transport system vs. a post-receptor defect in obesity. **J Clin Invest. e-letter**.
34. Nielsen S, Hensrud DD, Romanski S, Levine JA, Burguera B, Jensen MD. Body composition and resting energy expenditure in humans: role of fat, fat-free mass and extracellular fluid. **Int J Obes Relat Metab Disord** 2000 24:1153-1157
35. Thomas T, Burguera B, Melton LJ, Atkinson EJ, Riggs BL, Khosla S. 2001. Serum leptin levels and bone mineral density are directly related in women but not in men. In press. **Bone**. 29:114-120.
36. Vidal S, Cohen SM, Horvath E, Kovacs K, Scheithauer BW, Burguera B, Lloyd RV Subcellular localization of leptin in non-tumorous and adenomatous human pituitaries: an immuno-ultrastructural study. **J Histochem Cytochem** 2000 48:1147-52
37. Burguera B, Thomas T, Gori F, Evans G, , Riggs BL, Khosla S, Turner RT. Leptin inhibits bone resorption in vivo. 2001. **Endocrinology**. 142:3546-53
38. Burguera B, Couce ME. Leptin Access into the Brain: a Saturated Transport Mechanism in Obesity. 2001. **Physiol Behav**. 74:717-20.
39. Couce ME, Green D, Brunetto A, Achim C, Lloyd RV, Burguera B. Limited brain access for leptin in obesity. 2002. **Pituitary** 4:101-104
40. Lloyd RV, Jin L, Tsumanuma I, Vidal S, Kovacs K, Horvath E, Scheithauer B, Couce M, Burguera B. Leptin and Leptin receptor in anterior pituitary function. 2002. **Pituitary** 4: 33-48
41. Thomas T, Burguera B. Is leptin the link between fat and bone mass? 2002. **J Bone Miner Res**. 2002 17:1563-9.
42. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. 2003. **Ann Surg**. 238:467-84
43. Couce ME, Burguera B. Obesidad y Diabetes Mellitus Tipo 2: Un autentico Problema Macrosanitario. **Medicina Clinica**. 2004; 5 :3-6
44. Couce ME, Cottam DR, Teijeiro R, Esplen J, Schauer P, Burguera B Potential role of hypothalamic ghrelin in the pathogenesis of human obesity. **J Endocrinol Invest** 2006. 29:599-605
45. Couce ME, Cottam DR, Teijeiro R, Esplen J, Schauer P, Burguera B. Impact of Gastric Bypass Surgery on plasma ghrelin levels. A negative answer. **Obes Surg**. 2006 16:870-8.
46. Burguera B, Brunetto A, Garcia-Ocana A, Teijeiro R, Esplen J, Thomas T, Couce ME, Zhao A. Leptin increases proliferation of human osteosarcoma cells through activation of PI(3)-K and MAPK pathways. **Science Medical Monitor**. 2006; 12:BR341-349
47. Couce ME, Esplen J, Teijeiro R, Achim C, Burguera B. Ghrelin has trophic effects on human fetal neuroglial cells. An in vitro study. **Obesity and Metab**. 2006;2:87-94
48. Llompart-Pou JA, Raurich JM, Ibanez J, Burguera B, Barcelo A, Ayestaran JI, Perez-Barcelona J. Relationship between plasma adrenocorticotropin hormone and intensive care unit survival in early traumatic brain injury. **J Trauma**. 2007; 62:1457-61.

49. Llompart-Pou JA, Perez-Barcena J, Raurich JM, Burguera B, Ayestaran JI, Abadal JM, Homar J, Ibanez J. Effect of barbiturate coma on adrenal response in patients with traumatic brain injury. **J Endocrinol Invest.** 2007; 30:393-8.
50. Burguera B, Agusti A, Arner P, Baltasar A, Barbe F, Barcelo A, Breton I, Cabanes T, Casanueva FF, Couce ME, Dieguez C, Fiol M, Fernandez Real JM, Formiguera X, Fruhbeck G, Garcia Romero M, Garcia Sanz M, Ghigo E, Gomis R, Higa K, Ibarra O, Lacy A, Larrad A, Masmiquel L, Moizé V, Moreno B, Moreiro J, Ricart W, Riesco M, Salinas R, Salvador J, Pi-Sunyer FX, Scopinaro N, Sjostrom L, Pagan A, Pereg V, Sánchez Pernaute A, Torres A, Urgeles JR, Vidal-Puig A, Vidal J, Vila M. Critical assessment of the current guidelines for the management and treatment of morbidly obese patients. **J Endocrinol Invest.** 2007 30:844-52.
51. Riesco M, Pagan A, Piñero E, Barcelo A, Garcia Sanz M, Moreiro J, Pereg V, Urgeles JR, Vila M, Vidal-Puig A, Salinas R, Burguera B. The development of type 2 Diabetes Mellitus in the context of morbid obesity is not related to differences in inflammatory status. **Obesity and Metabolism** 2008; 4: 193-198.
52. Riesco M; Barceló A; Vila M; Belmonte M; Ruiz O; Lopez-Escribano H; Madany E; and Burguera B. Plasma levels of visfatin and obestatin in morbidly obese subjects with and without T2 diabetes mellitus. **Obesity and Metabolism** 2009; 5: 9-12.
53. Tur J, Burguera B. Therapeutic evaluation of the morbidly obese patient. **Endocrinol Nutr.** 2009;56:452-8
54. Llompart-Pou JA, Pérez, Gerardo; Pérez-Bárcena, J; Brell, M; Ibáñez, J; Riesco, M; Abadal, J; Homar, J; Marsé, P; Ibáñez, J; Burguera, B; Raurich, J. traumatic brain injury, cerebral microdialysis, total serum cortisol, brain interstitial cortisol. **J Endocrinol Invest** En prensa.
55. Frontera M, Burguera B. Papel del Intestino Delgado en la Resolución de la DMT2 después de cirugía bariátrica. Educación Diabetológica Profesional. XIX 2 2009. 37-42
56. Llompart-Pou JA, Pérez G, Pérez-Bárcena J, Brell M, Ibáñez J, Riesco M, Abadal JM, Homar J, Marsé P, Ibáñez J, Burguera B, Raurich JM. Correlation between brain interstitial and total serum cortisol levels in traumatic brain injury. A preliminary study. **J Endocrinol Invest.** 2010; 33:368-72.
57. Llompart-Pou JA, Pérez G, Raurich JM, Riesco M, Brell M, Ibáñez J, Pérez-Bárcena J, Abadal JM, Homar J, Burguera B Loss of cortisol circadian rhythm in patients with traumatic brain injury: a microdialysis evaluation. **Neurocrit Care.** 2010.13:211-6
58. Brell M, Ibáñez J, Felpete A, Burguera B, Frontera M, Couce ME. Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas. **Brain Tumor Pathol.** 2011 Feb 18.
59. Fiol M, Amézaga R, Arós F, Burguera B, Sala J, Bruguera J, Valle V, Sanz G, Covas MI, Fitó M, Martí H, Elosua R, Schröder H, Marrugat J. Body mass index in the prognosis of first myocardial infarction]. **Med Clin (Barc).** 2010; ;135:631-6
60. Tur J, Escudero A, Iglesias L, Alos M, Luque L, Burguera B. Key points in the start and conduct of a clinical trial. From question to reality in an investigator-initiated clinical trial (I). **Endocrinol Nutr.** 2011; 58:291-8.
61. Tur J, Alòs M, Iglesias L, Luque L, Colom A, Escudero A, Martínez D, Pagán A, Ugarriza E, Frontera M, Nicola G, Palomero A, Tofé S, Urgeles JR, Barceló A, Couce M, De La Peña M, Fiol M, Cortés B, Terés E, Tumbarello A, Álvarez C, Salinas R, Pereg V, González X, Burguera B . TRAMOMTANA (Tratamiento Multidisciplinar de la Obesidad Mórbida: Medicamentos, Terapia de comportamiento, Apoyo Nutricional y Actividad física). De la pregunta a la realidad de un ensayo clínico investigador iniciado (II). **Endocrinol Nutr.** 2011; 58:299-307
62. Burguera B; Colom A; Piñero E; Yanez A; Caimari M, Juan Tur J, Frontera M, Couce M, Cardó E, Aguiló A, Burguera A, Cabeza E. ACTYBOSS: Activity, Behavioral Therapy in Young Subjects. After-school intervention Pilot Project on obesity prevention. Incentive-driven children obesity prevention program. **Obes Facts.** 2011;4 :400-6.

63. Piérola J, Alemany A, Yañez A, de-la-Peña M, Sánchez-de-la-Torre M, Esquinas C, Pérez-Gutierrez C, Burguera B, Barbé F, Barceló A NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea. **Respir Med.** 2011; 105:1748-54
64. Llompарт-Pou JA, Fernández-de-Castillo AG, Pérez-Bárcena J, Marsé P, Rodríguez-Yago M, Barceló A, Raurich JM. Stress hyperglycaemia in critically ill patients: Potential role of incretin hormones; a preliminary study. **Nutr Hosp.** 2012; 27:130-7.
65. Lecube A, Burguera B, Rubio MA; en nombre del Grupo de Trabajo de Obesidad de la Sociedad Española de Endocrinología y Nutrición (GOSEEN). Breaking therapeutic inertia: should metabolic surgery be considered one more option for the treatment of type 2 diabetes mellitus? **Endocrinol Nutr.** 2012 Apr 13.
66. Burguera B, Ruiz de Adana JC. Long term effects of bariatric surgery. **Cir Esp.** 2012; 90 :275-276.
67. Burguera B, Colom A, Piñero E, Yanez A, Caimari M, Tur J, Frontera M, Couce M, Cardo E, Aguiló A, Burguera A, Cabeza E ACTYBOSS: activity, behavioral therapy in young subjects--after-school intervention pilot project on obesity prevention. **Obes Facts.** 2011; 4:400-6.
68. Caixàs A, Lecube A, Morales MJ, Calañas A, Moreira J, Cordido F, Díaz MJ, Masmiquel L, Moreno B, Vidal J, Goday A, Arrizabalaga JJ, García-Luna PP, Iglesias P, **Burguera B**, Rubio MA, Monereo S; Group for the Study of Obesity of the Spanish Endocrinology and Nutrition Society (SEEN), Crosby RD, Kolotkin RL. Weight-related quality of life in Spanish obese subjects suitable for bariatric surgery is lower than in their North American counterparts: a case-control study. **Obes Surg.** 2013; 23 :509-14. doi: 10.1007/s11695-012-0791-0
69. Tur, J. J., Escudero, A. J., Alos, M. M., Salinas, R., Terés, E., Soriano, J. B., Nicola, G., Urgelés, J. R., Pagán, A., Cortes, B., González, X. and Burguera, B. (2013), One year weight loss in the TRAMOMTANA study. A randomized controlled trial. **Clinical Endocrinology.** doi: 10.1111/cen.12109
70. Tur JJ, Escudero AJ, Romaguera D, Burguera B. How can we predict which morbidly obese patients will adhere to weight-loss programs based on life style changes? **Endocrinol Nutr.** 2013 Jun-Jul;60:297-302
71. Caixàs A, Lecube A, Burgura B et al; Obesity Working Group of the Spanish Society of Endocrinology and Nutrition (GOSEEN). Where are obese people happier? **Endocrinol Nutr.** 2014; 61(1):1-2. 2013.
72. Vázquez C, Botella-Carretero JI, Corella D, Ros E, Salas-Salvadó J, Burguera B, Estruch R, Fernández-Real JM, Fuentes F, Pastor O, and Felipe F Casanueva. White fish reduces cardiovascular risk factors in patients with Metabolic Syndrome. The multicenter WISH-CARE study* **Nutr Metab Cardiovasc Dis.** 2014 Mar; 24:328-35.
73. Ali Aminian M.D., Stacy A Brethauer M.D., John P Kirwan Ph.D. Sangeeta R Kashyap M.D., Bartolome Burguera M.D. Ph.D., Philip R Schauer M.D. How Safe is Metabolic/Diabetes Surgery?. **RESEARCH LETTER in Press Diabetes, Obesity and Metabolism.** 2015
74. Ali Aminian M.D., Stacy A Brethauer M.D., John P Kirwan Ph.D. Sangeeta R Kashyap M.D., Bartolome Burguera M.D. Ph.D., Philip R Schauer M.D.. Outcomes of bariatric surgery in type 2 diabetic patients with diminished pancreatic secretory reserve. **Acta Diabetol** DOI 10.1007/s00592-014-0642-7
75. Bartolomé Burguera MD, PhD; Juan Jesús Tur PhD; Antonio Jorge Escudero BS; María Micaela MD; Alberto Pagán MD; Baltasar Cortés BS; Xavier Francesc González MD, PhD; Joan B. Soriano MD, PhD. AN INTENSIVE LIFE STYLE INTERVENTION IS AN EFFECTIVE TREATMENT OF MORBID OBESITY. THE TRAMOMTANA Study: A Two-year Randomized Controlled Clinical Trial. **International J. Endocrinology.** 2016
76. Aminian A, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J, Brethauer SA, Schauer PR. Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis. **Ann Surg.** 2016 Mar 8. PMID:26967631

77. Aminian A, Kashyap SR, Burguera B, PUNCHAI S, Sharma G, Froylich D, Brethauer SA, Schauer PR. Incidence and Clinical Features of Diabetic Ketoacidosis After Bariatric and Metabolic Surgery. **Diabetes Care**. 2016 Jan 28. PMID: 26822327
78. Corcelles R, Boules M, Froylich D, Hag A, Daigle CR, Aminian A, Brethauer SA, Burguera B, Schauer PR. Total Weight Loss as the Outcome Measure of Choice After Roux-en-Y Gastric Bypass. **Obes Surg**. 2016 Jan 23.
79. Goday A, Bellido D, Sajoux I, Crujeiras AB, Burguera B, García-Luna PP, Oleaga A, Moreno B, Casanueva FF. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. **Nutr Diabetes**. 2016 Sep 19;6(9):e230.
80. Haskins IN, Corcelles R, Froylich D, Boules M, Hag A, Burguera B, Schauer PR, Kroh M, Brethauer SA. Primary Inadequate Weight Loss After Roux-en-Y Gastric Bypass Is not Associated with Poor Cardiovascular or Metabolic Outcomes: Experience from a Single Institution. **Obes Surg**. 2017 Aug 10.
81. Aminian A, Andalib A, Khorgami Z, Kashyap SR, Burguera B, Schauer PR, Brethauer SA. A nationwide safety analysis of bariatric surgery in nonseverely obese patients with type 2 diabetes. **Surg Obes Relat Dis**. 2016 Jul;12(6):1163-70.
82. Kirwan JP, Aminian A, Kashyap SR, Burguera B, Brethauer SA, Schauer PR. Bariatric Surgery in Obese Patients With Type 1 Diabetes. *Diabetes Care*. 2016 Jun;39(6):941-8
83. Chang JJ, Bena J, Kannan S, Kim J, Burguera B, Kashyap SR. LIMITED CARBOHYDRATE REFEEDING INSTRUCTION FOR LONG-TERM WEIGHT MAINTENANCE FOLLOWING A KETOGENIC, VERY-LOW-CALORIE MEAL PLAN. **Endocr Pract**. 2017 Feb 22.
84. Zambrano J, Burguera B. Can obesity counseling be effectively incorporated into a 20-minute office visit?" **Cleveland Clinic Journal of Medicine**. In Press

Invited, Non-Peer Reviewed

1. Burguera B, Caro JF. Mechanism of action of insulin: First Chapter. **Endocrinologia** 1990; 37(1):5-7.
2. Burguera B, and Jensen MD. Obesity, is the brain responsible? 1998 **Curr Opin in Gastroenterol** 14:147
3. Burguera B, Couce ME, Lloyd RV. Leptin receptor and the Brain. A tale of body weight regulation.2001 **Curr Opin Endocrinol Diabetes**. 7:225-230
4. Burguera B, Couce ME. Leptin Access into the Brain: a Saturated Transport Mechanism in Obesity. 2001 **Physiol and Behavior**.74:717-20.
5. Burguera B. Es la Cirugía Bariátrica el único tratamiento para la Obesidad Mórbida? Monográfico Actualización de la Obesidad. **Revista Hormona y Factores de Crecimiento**. 2004.
6. Estefanía Piñero Bartolomé Burguera. Epidemia de Obesidad en EEUU y la realidad Española. Libro Ponencias. IV Reunion Internacional “ **La alimentación y la Nutricion del Siglo XXI**. Baiona. Nov 2006
7. Gonzalez Boillos M, Pereg V, Burguera B. Novedades en Terapia hipoglucemiante. Fármacos con acción incretina. **Endocrinol Nutr**, 2007; 54:1-000
8. Quevedo J, Tur J, Soler G, Burguera B. Utilidad de los fármacos antiobesidad en el tratamiento de la diabetes tipo 2». **Avances en Diabetología**. 26: 161-166, 2010
9. Burguera B. Diabetes Mellitus Tipo 2 ¿Debe ser la cirugía metabólico parte del armamentarium terapéutico? **Medicina Balear** 2012; 27; 5-8

10. Luque L, Riera A, Burguera B: “Cirugía bariátrica y diabetes mellitus tipo 2 ¿son todas las técnicas quirúrgicas iguales? **Avances en Diabetología**, 2013

Book Chapters

1. Casabiell X, Burguera B, Muruais C, Garcia RVG, Casanueva FF, Dieguez C, Prolactina Cortada: **Estudio de sus Mecanismos de Formación in Vitro**. In: Forteza J, editor. IV FISss Annual Meeting, 1989; 88-104.
2. Casanueva FF, Burguera B, Casabiell X, Alvarez C, Muruais C, Dominguez F, Dieguez C. Levels of neuroendocrine and pharmacologic regulation of growth hormone secretion. In: Muller EE MacLeod RM, editors. **Neuroendocrine Perspectives**, Vol 1. Amsterdam: Elsevier, 1989; 177-188.
3. Muruais C, Burguera B, Casabiell X, Peñalva A, Mallo F, Casanueva FF, Dieguez C. Administration of glucocorticoids and GH secretion in man. In: Casanueva FF, Dieguez C, editors. **Recent Advances in Basic and Clinical Neuroendocrinology**. Excerpta medica. Amsterdam: Elsevier, 1990; 233-239.
4. Burguera B, Caro JF. Alterations in insulin receptors and glucose transporters in obesity and type II diabetes. In: Shafir E, editor. **Frontiers in Diabetes Research: Lessons from Animal Diabetes**, Vol. 6. Oxford: Smith-Gordon and Company Ltd., 1990: 269-276.
5. Mallo F, Alvarez C, Burguera B, Lamas JA, Señaris R, Dominguez C. Regulation of growth hormone secretion by thyroid hormones and estrogens. In: de la Cruz LF, Garcia Lara MT, editors. **Recent Advances in Growth and Reproduction**. Santiago: University Press, 1991; 55-63.
6. Cordido F, Mallo F, Casabiell X, Alvarez C, Señaris R, Burguera B, Dieguez C, Casanueva FF. In: de la Cruz LF, Garcia Lara MT, editors. **Neuroregulation of GH Secretion in Obesity**. Santiago: University Press, 1991; 93-103.
7. Burguera B, Muruais C, Casabiell X, Mallo F, Alvarez C, Dieguez C, Casanueva FF. Dual and selective effect of dexamethasone upon GH secretion. In: Thorner FH, editor. **Ares-Serono Symposia**, Vol 58. New York: Raven Press 1989; 90-95.
8. Burguera B, Couce ME, Caro JF. Papel del IGF-II R en la regeneración hepática. In: Dieguez C, Casanueva FF, editors. **Advances Endocrinología Molecular y Celular**. Madrid: Fundación Ramon Areces, 1992; 221-236.
9. Burguera B, Parzianello N, Caro JF. Estudio de los niveles de GLUT-2 in NIDDM. In: Dieguez C, Casanueva FF, editors. **Fronteras en Endocrinología**. Madrid: Diaz Santos, 1992; 19-29.
10. Burguera B, Werner H, Couce M, Robert CT, Jr., LeRoith D, Caro JF. Physiology of the insulin-like growth factor I and insulin-like growth factor II/Mannose 6-phosphate receptors. In: de la Cruz LF, editor. **Regulation of Growth Hormone and Somatic Growth**. Amsterdam: Elsevier, 1992; 271-294.
11. Burguera B. Obesity Prevention. Endo text. (Eds. Jose Caro and Leslie DeGroot). WWW.ENDOTEXT.ORG
12. Horowitz M, Levy E, Genevro J, Kassam A, Burguera B. Petrosal Sinus Sampling For Cushing’s Disease.. Book Chapter in **Interventional Radiology**. (Horowitz M. Ed). 2005
13. Josefina Olivares, Bartolome Burguera. Pubertad y Homeostasis Metabólica. **Monografía PUBERTAD**. (Editores: C. Dieguez/R. Yturriaga). 2006
14. Material Educativo para pacientes de Cirugía Bariátrica. **Editado por Novartis Laboratorios**. 2006
15. Diaz S, Burguera B. Actitud ante el Debut de una Diabetes Mellitus. Perspectiva General del Tratamiento. **La Diabetes Mellitus en la Practica Clinica**. (Ed. Javier Tebar/Fernando Escobar). 2009

16. Burguera B. *Obesidad M3rbida: Tratamiento quir3rgico y sus repercusiones nutricionales y metab3licas*. Manual de Endocrinología para residentes. Ed. Sociedad Espa3ola de Endocrinología. 2009
17. Burguera B. Tur J. *Medical Management of Obesity*". 2nd edition of *Minimally Invasive Bariatric Surgery*. Springer Science + Business Media, (Ed Philip R. Schauer, Bruce D. Schirmer, and Stacy A. Brethauer) 2014

Editorials

1. Burguera B, Ruiz de Adana JC. Long term effects of bariatric surgery. **Cir Esp.** 2012; 90 :275-276.

Letters

1. Burguera B & Couce ME. 2000. Leptin access into the brain: a saturated transport system vs. a post-receptor defect in obesity. **J Clin Invest. e-letter.**

Abstracts

(author(s), title of abstract, journal and year, volume, pages) (Abstract presentations: also list meeting, location, and meeting date)

1. Casanueva FF, Borrás C, **Burguera B**, Muruais C, Fernández M, Devesa J. Steroids and neuroendocrine function in anorexia nervosa. VII World Steroids Congress, Madrid, Spain, 1986.
2. Dieguez C, Villaneuva L, Díaz Y, **Burguera B**, Alvarez C, Scanlon M, Casanueva FF. Free fatty acids (FFA) inhibit GH secretion at pituitary level. First European Congress of Endocrinology, Copenhagen, Denmark, 1987.
3. Pe3alva A, Burguera B, Casabiell J, Mallo F, Casanueva FF, Dieguez C. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycaemia on GHRH-induced GH secretion in man. **III International Meeting of Neuroendocrinology**, Barcelona, Spain, 1988.
4. Casabiell X, Burguera B, Muruais C, Alvarez C, Dieguez C, Casanueva FF. Cleaved PRL: mechanism of in vitro formation. **III International Meeting of Neuroendocrinology**, Barcelona, Spain, 1988.
5. Casanueva FF, Burguera B, Casabiell X, Pe3alva A, Dieguez C. Neuroregulation of prolactin (PRL) secretion in normal human subject. **Eighth International Congress of Endocrinology**, Japan, 1988.
6. Burguera B, Muruais C, Dieguez C, Casanueva FF. Dual and selective effect of dexamethasone upon GH secretion in man. **International Symposium on Hormonal Regulation of Growth**, Vienna, Austria, 1988.
7. Burguera B, Muruais C, Dieguez C, Casabiell X, Casanueva FF. Potent stimulatory effect of glucocorticoids on growth hormone (GH) secretion in man. **71st Annual Meeting of the Endocrine Society**, Seattle, WA, 1989.
8. Dieguez C, Burguera B, Mallo F, Alvarez C, Sanchez-Franco F, Casanueva FF. Dual effects of glucocorticoids on the neuroregulation of growth hormone secretion in the rat. **9th International Symposium of the Journal of Steroid Biochemistry**, Spain, 1989.
9. Muruais C, Burguera B, Casabiell X, Pe3alva A, Casanueva FF, Dieguez C. Acute administration of glucocorticosteroids (GC): a new and peculiar stimulus of growth hormone (GH) secretion in man. **4th Meeting of the European Neuroendocrine Association**, Spain, 1989.
10. Benitez L, Mallo F, Alvarez C, Burguera B, Sanchez-Franco F, Dieguez C. Effect of Bombesin on in vitro GH secretion and its modulation by estrogens. **4th Meeting of the European Neuroendocrine Association**, Spain, 1989.
11. Alvarez C, Burguera B, Mallo F, Benitez L, Sanchez-Franco F, Casanueva FF, Dieguez C. Effect of acute and chronic dexamethasone administration on in vivo GH responses to GHRM in normal and hypophysectomized-transplanted rats. **4th Meeting of the European Neuroendocrine Association**, Spain, 1989.

12. Mallo F, Alvarez C, Burguera B, Benitez L, Lamas JA, Casanueva FF, Dieguez C. Modulatory role of peripheral signals on in vivo GH response to GHRP-6 in the rat. **4th Meeting of the European Neuroendocrine Association**, Spain, 1989.
14. Werner H, Shen-Orr Z, Burguera B, Stannard B, Roberts CT Jr, LeRoith D. Experimental diabetes increases IGF-I receptor gene expression and binding in the rat kidney. **50th Annual Meeting of the American Diabetes Association**, Atlanta, GA, 1990.
15. Burguera B, Werner H, Sclar M, Roberts CT Jr, LeRoith D. IGF-II R gene expression during liver regeneration. **50th Annual Meeting of the American Diabetes Association**, Atlanta, GA, 1990.
16. Burguera B, Werner H, Roberts CT Jr, Caro JF, LeRoith D. IGF II receptor gene expression during liver regeneration. **II International Symposium on Endocrinology Under 35**, Italy, 1990.
17. Usala AL, Usala ST, Powel J, Madigan T, Cefalu W, Burguera B, Sinha MK. Intravenous (IV) but not subcutaneous (SC) IGF-I improves clinically severe insulin resistance (IR) in vivo and adipocyte IR in vitro. **Symposium on Insulin IGFs and Their Receptors**, Woods Hole, MA, 1992.
18. Burguera B. Neuroregulation of appetite. **2nd Reunion Medicos Gallegos**. Orense, Spain 1997
19. Thomas T, Burguera B, Melton LJ, Atkinson EJ, Riggs BL, Khosla S. 1998. Fat body mass and bone mineral density are directly related both in women and in men, but serum leptin levels and bone mineral density are directly related only in women. **Second Joint Meeting of the ASBMR and the IBMS**. San Francisco, 1998
20. Llompart Pou, JA, Pérez Aizcorreta O, Pérez Bárcena J, Raurich Puigdevall JM, Burguera Bartolomé*, Abadal Centellas JM, Homar Ramírez J, Ibáñez Juvé J. **Congreso Nacional de Medicina Intensiva**. 2006
21. Marga Frontera, Marta Couce, Ana Felpete, Bartolomé Burguera. STUDY ON THE EXPRESSION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR IN HUMAN HYPOTHALAMUS. Comunicación Reunion CIBEROBN. La Toja Septiembre 09.
22. Alvarez C, Burguera B, Casabiell X, Casanueva FF, Dieguez C. Estudio del papel regulador de los acidos grasos libres (FFA) sobre la secreción de GH. **XXIII Reunión Nacional de la Sociedad Española de Endocrinología**, Granada, Spain, 1987.
23. Burguera B, Muruais C, Tome M, Devesa J, Dieguez C, Casanueva FF. Dependiendo del tiempo de administración y dosis, dexametasona potencia o bloquea la secreción de GH inducida por GHRH. **XXIII Reunión Nacional de la Sociedad Española de Endocrinología**, Granada, Spain, 1987.
24. Muruais C, Burguera B, Casabiell X, Dieguez C, Casanueva FF. Estudio de la secreción adenohipofisaria ante stress psiquico. **I Encontro Luso-Galaico de Endocrinología**, Oporto, Portugal, 1987.
25. Casabiell X, Burguera B, Alvarez C, Dieguez C, Casanueva FF. Estudio de la influencia de los acidos grasos libres en la secreción de GH en la rata. **I Encontro Luso-Galaico de Endocrinología**, Oporto, Portugal, 1987.
25. Alvarez C, Burguera B, Casabiell X, Dieguez C, Casanueva FF. Formas moleculares de PRL. **I Encontro Luso-Galaico de Endocrinología**, Oporto, Portugal, 1987.
27. Muruais C, Peñalva A, Burguera B, Dieguez C. Papel de la somatostatina en el efecto inhibitor de los acidos grasos libres y la glucosa sobre la liberación de GH inducida por GHRH. **VII Congreso nacional de Endocrinología**, Bilbao, Spain, 1988.
28. Burguera B, Muruais C, Casabiell X, Alvarez C, Dieguez C, Casanueva FF. Control dual y selectivo de los glucocorticoids sobre la liberación de GH. **VIII Congreso Nacional de Endocrinología**, Bilbao, Spain, 1988.

29. Mallo F, Alvarez C, Burguera B, Benitez L, Ibañez R, Muruais C, Casanueva FF, Dieguez C. Papel modulador de los estrógenos sobre la neuroregulación de GH por GHRH, bombesina y neurotensina. **II Congreso Luso-Galaico de Endocrinología**, Santiago, Spain, 1988.
30. Peñalva A, Muruais C, Burguera B, Casabiell X, Dieguez C, Casanueva FF. La activación colinérgica central por piridostigmina induce una respuesta positiva de GH a dosis ineficaces de GHRH. **II Congreso Luso-Galaico de Endocrinología**, Santiago, Spain, 1988.
31. Zalvide J, Briones R, Señaris R, Burguera B, Dieguez C, Dominguez F. Efecto de la dexametasona sobre la producción de protimosina. **II Congreso Luso-Galaico de Endocrinología**, Santiago, Spain, 1988.
32. Burguera B, Raju SM, Abdallah S, Mooney M, Mustafa SJ, Caro JF. Does proinsulin crossreact with the IGF's receptors accelerating heart disease? **3rd Annual Research Day**, Department of Medicine, ECU School of Medicine, Greenville, NC, 1989.
33. Burguera B, Caro JF. Mechanism of insulin resistance in the liver of type-II diabetic patients. **10th National Endocrine Meeting**, Spain, 1991.
34. Burguera B, Stanzak R, Sliker L, Leggett-Frazier N, Long S, Caro JF. Is the low level of Glut-2 gene expression present in impaired glucose tolerant patients (IGT) preventing or inducing non-insulin dependent diabetes mellitus? **73rd Annual Meeting of the Endocrine Society**, Washington, DC, 1991.
35. Stanzak R, Burguera B, Caro JF. Developmental regulation of GLUT-2 glucose transporter expression in the human liver. **5th Annual Research Day**, Department of Medicine, ECU School of Medicine, Greenville, NC, 1991.
36. Burguera B. The regulation of GLUT-2 in the liver. **Mid-Atlantic Diabetes Research Symposium at NIH**, Bethesda, MD, 1991.
37. Usala AL, Madigan T, Burguera B, Caro JF, Butler P. Insulin-like growth factor I (IGF-I) treatment for insulin resistant ketoacidosis in an adolescent girl with Type I diabetes mellitus. **American Pediatric Society**, Baltimore, MD, 1992.
38. Usala AL, Madigan T, Burguera B, Caro JF, Powell J, Cunningham P, Butler P. Effect of IGF-I on lipolysis, ketogenesis and glycemia in an adolescent with Type I diabetes mellitus and massive episodic insulin resistance. **74th Annual Meeting of the Endocrine Society**, San Antonio, TX, 1992.
39. Burguera B, Dudek RW, Stanzak R, Couce ME, Caro JF. GLUT-2 expression in NIDDM patients. **6th Annual Research Day**, Department of Medicine, ECU School of Medicine, Greenville, NC, 1992.
40. Usala AL, Madigan T, Burguera B, Powell JC, Ricker AT, Usala SJ. Intravenous, but not subcutaneous, insulin-like growth factor I (IGF-I) induces sustained insulin sensitivity in severely resistant patients. **American Pediatric Society**, Washington, DC, 1993.
41. Usala AL, Powell J, Madigan T, Burguera B, Usala SJ. Intravenous or subcutaneous IGF-I therapy induces symptomatic hypophosphatemia in patients with severe insulin resistance. **75th Annual Meeting of the Endocrine Society**, Las Vegas, NV, 1993.
42. Burguera B, Tapscott EB, Elton CW, Carey J, Usala AL, Pories WJ, Sakano K, Dohm GL. IGF-II stimulation of glucose uptake in human muscle is not mediated by the IGF-II receptor (IGF-II/Man 6-P R). **75th Annual Meeting of the Endocrine Society**, Las Vegas, NV, 1993.
43. Burguera B, Usala AL, Pories WJ, Dohm GL. IGF-II effect on glucose uptake in human muscle. **7th Annual Research Day**. Department of Medicine, ECU School of Medicine, Greenville, NC, 1993.
44. Burguera B. Therapeutic effect of IGF-1 in diabetes. **37th National Endocrine Society Meeting**. Toledo, Spain, 1994.

45. Burguera B, Usala AL. Clinical use of IGF-I as a novel therapy in the treatment of diabetic ketoacidosis and insulin resistance. **The Connecticut Chapter of the American College of Physicians**, Trumbull, CT 1995.
46. Burguera B, Couce ME, Parisi JE, Jensen MD, Lloyd RV. Localization of leptin receptor in the human brain. **79th Annual Meeting of the Endocrine Society**, Minneapolis, 1997.
47. Guo Z., Burguera B, Jensen MD Triglyceride synthesis rate in skeletal muscle measured using 13-C fatty acids. **FASEB**. New Orleans. 1997.
48. Burguera B, Couce ME, Lamsam J, Jensen MD, Lloyd RV. The long form of the leptin receptor (OBpRb) is widely expressed in the human brain. **80th Annual Meeting of the Endocrine Society**, New Orleans, 1998
49. Thomas T, Gori F, Jensen MD, Burguera B, Riggs BL. 1998. Mechanism of fat mass effects on bone mass: leptin as a promoter of osteoblastic progenitor differentiation. **80th Annual Meeting of the Endocrine Society**, New Orleans, 1998
50. L. Jin, Burguera B, Couce ME, Lamsam J, K. Kovacs, Lloyd RV. Leptin receptor (OB-Rb) expression in normal and neoplastic human pituitaries. Regulation of pituitary cell proliferation by leptin.. **80th Annual Meeting of the Endocrine Society**, New Orleans, 1998
51. Burguera B, Thomas T, Gori F, Evans G, Lamsam J, Laakso K, Khosla S, Riggs, LW, Turner RT. Leptin inhibits bone resorption in vivo. **NAASO Annual Meeting**. Charleston, 1999
52. Burguera B, Curran G, Couce ME, Lamsam J, Cleary M, Poduslo J. Obesity is associated with a decreased of leptin transport across the blood brain barrier and up regulation of leptin receptor in the hypothalamus. **NAASO Annual Meeting**. Charleston, 1999
53. Couce ME., Espleen J, Brunetto A, Kates C, Green D, Achim C, Burguera B. Both, Leptin and Ghrelin have a trophic effect on developing neurons and glial cells. **NAASO Annual Meeting**. Quebec 2000.
54. Couce ME, Cottam DR, Teijeiro R, Esplen J, Schauer P, Burguera B. Plasma Ghrelin levels after gastric bypass Surgery. **American Diabetes Association's 63rd Scientific Sessions**. June 2003. New Orleans, Louisiana.
55. Couce ME, Teijeiro R, Esplen J, Burguera B. Human Obesity Is Associated with Increased Hypothalamic Synthesis of Ghrelin **American Diabetes Association's 63rd Scientific Sessions**. June 2003. New Orleans, Louisiana.
56. Couce ME, Goodpaster B, Teijeiro R, Esplen J, Cameron J, Burguera B. Impact of Resistance Training on Ghrelin Levels in Primates. **American Diabetes Association's 63rd Scientific Sessions**. June 2003. New Orleans, Louisiana.
57. Couce ME, Teijeiro R, Esplen J, Burguera B. The role of central ghrelin in human obesity **American Society of Neuropathology**. June 2003. Orlando, Florida
58. Llompart Pou, JA, Pérez Aizcorreta O, Pérez Bárcena J, Raurich Puigdevall JM, Burguera Bartolomé*, Abadal Centellas JM, Homar Ramírez J, Ibáñez Juvé J. **Congreso Nacional de Medicina Intensiva**. 2006
59. *Tur J, Burguera B, Escudero AJ, Alós MM, Ugarriza E, Luque L, Pereg V, Urgelés JR, Tofe S, Iglesias L, Cañellas F, Couce M, Guevara R, Sampol M, Palomero A, Cortés B, Colom A, Martínez D, González X. Tratamiento Multidisciplinar de la Obesidad Mórbida: Terapia de Conducta, Nutrición y Actividad Física. El Estudio TRAMOMTANA.. *Endocrinol Nutr.* 2011; 58, (Espec Cong) 1.
60. *Escudero AJ, Tur J, Alós MM, Ugarriza E, Luque L, Pereg V, Urgelés JR, Tofe S, Iglesias L, Cañellas F, Couce M, Guevara R, Sampol M, Palomero A, Cortés B, Colom A, Martínez D, Burguera B. ATTOM: Abordaje Telemático Interdisciplinar de la Obesidad Mórbida” *Endocrinol Nutr.* 2011; 58, (Espec Cong) 65.

61. *Colom A, Cabeza E, Yáñez A, Frontera M, Cortés B, Martínez D, Burguera A, Luque L, Iglesias L, Escudero AJ, Tur J, Caimari M, Cardo E, Aguiló A, Burguera B. Base-Line of ACTYBOSS (Activity, Conductual Therapy in Young Subjects) Prospective, Multicenter, Cluster randomized, paired and controlled, after-school community trial on Obesity Prevention. ” *Endocrinol Nutr.* 2011; 58, (Espec Cong) 86.
62. *Luque L, Iglesias L, Burguera B, Colom A, Tur J, Escudero AJ, Cortés B, Martínez D. Estudio Ses Passes Ses Pases. *Endocrinol Nutr.* 2011; 58, (Espec Cong) 92.
63. Tur J, Burguera B, Escudero AJ, Alós MM, Ugarriza E, Luque L, Iglesias L, Palomero A, Colom A, Cañellas F. Factores Predictivos de éxito/fracaso en la terapia interdisciplinar intensiva en pacientes obesos mórbidos participantes en el Estudio TRAMOMTANA. *Rev Esp Obes.* 2011; 9, 2, 115.
64. Escudero AJ, Burguera B, Alós MM, Ugarriza E, Luque L, Iglesias L, Palomero A, Colom A, Cañellas F, Tur J. Sistema de análisis de test psicométricos y de calidad de vida relacionada con la salud mediante herramientas de predicción en el estudio TRAMOMTANA. *Rev Esp Obes.* 2011; 9, 2, 104.
65. Alós MM, Tur J, Escudero AJ, Ugarriza E, Colom A, Cortés B, Iglesias L, Martínez D, Luque L, Burguera B. estandarización de una pauta de preparación a la incorporación de actividad física en una población de obesos mórbidos participantes en el Estudio TRAMOMTANA. *Rev Esp Obes.* 2011; 9, 2, 116.
66. Ali Aminian, Christopher R Daigle, John P Kirwan, Bartolome Burguera, Sangeeta R Kashyap, Stacy A Brethauer, Philip R Schauer. Outcomes of Bariatric Surgery in Diabetic Patients with Diminished Pancreatic Secretary Reserve. American Diabetes Association Meeting. San Diego. 2014.
67. Burguera B, Hobbs TM, Chagin KM, Pantalone KM, Kong SX, Wells BJ, Bouchard J, Kattan MW, Sakurada B, Milinovich A, Weng W, Bauman JM, Zimmerman RS. The Prevalence and Recognition of Obesity and its Associated Comorbidities in a Large U.S. Integrated Health System. TOS. New Orleans. 2016

PATENTS

US patent #: 5,586,501. Dec 24th, 1996
 Dissapearing ink marking system